Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report

Giulia Costanzo; Andrea Giovanni Ledda; Alessandra Ghisu; Matteo Vacca; Davide Firinu; Stefano Del Giacco

doi:10.3390/vaccines10010013

Eosinophilic Granulomatosis with Polyangiitis Relapse after COVID-19 Vaccination: A Case Report

Vaccines (Basel). 2021 Dec 23;10(1):13. doi: 10.3390/vaccines10010013.

Authors

Giulia Costanzo¹, Andrea Giovanni Ledda¹, Alessandra Ghisu¹, Matteo Vacca¹, Davide Firinu¹, Stefano Del Giacco¹

Affiliation

¹ Department of Medical Sciences and Public Health, University of Cagliari, 09131 Cagliari, Italy.

Abstract

Background: We here describe the case of a 71-year-old Caucasian woman previously diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA) that had been treated with Mepolizumab, an anti-IL5 monoclonal antibody, since 2019 with a good clinical response.

Methods: She had a mild COVID-19 in December 2020 and she tested negative for SARS-CoV-2 infection in only late January 2021. In April 2021 she received the first dose of mRNA BNT162b2 vaccine. Ten days later she developed myalgia, dyspnea and numbness of the limbs due to a relapse of EGPA that occurred during Mepolizumab treatment.

Keywords: COVID-19; EGPA; mRNA BNT162b2 vaccine; relapse; vaccine.

Publication types

Case Reports